Supreme Court directs Centre to review safeguards against unethical pharmaceutical marketing within two months

The petitioners invoked Article 32, alleging that pharmaceutical companies used gifts, hospitality, sponsored travel and other inducements to influence medical professionals’ prescribing practices, with potential consequences for public health and medicine affordability

They sought statutory force for the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) or interim judicial guidelines, contending that its voluntary character had made it ineffective

The Union submitted that the UCPMP, 2024 had strengthened disclosure, complaint-handling and oversight mechanisms, and proposed a Committee to examine the regulatory framework

The petitioners and intervenors sought an opportunity to make representations to that Committee

Whether the existing framework for regulating pharmaceutical marketing practices required further examination and strengthening in light of concerns about its effectiveness and enforcement

Whether the Court should direct a consultative, time-bound examination by the Union, rather than prescribe a regulatory policy itself, while safeguarding the public interest in health

Article 21 protects the right to health as an aspect of the right to life, and Articles 32 and 142 empower the Supreme Court to issue appropriate directions to protect constitutional rights and secure effective relief

The separation-of-powers principle requires the Court to avoid substituting its policy choices for those of the executive, particularly where regulatory design involves technical expertise and competing considerations; judicial restraint does not, however, require indifference to concerns directly affecting public health

The existing framework included the UCPMP, 2024 for pharmaceutical marketing and the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, which restrict specified benefits from industry to medical practitioners and provide for disciplinary consequences

No precedent was cited.

The Court considered the material before it sufficient to warrant a closer examination, observing that the effectiveness of regulation depends not merely on prescribed standards but also on implementation, monitoring and enforcement

Because selecting the appropriate statutory and regulatory framework was primarily an executive policy function, the Court declined to prescribe a substantive regulatory model. It instead considered that a structured consultation—taking account of the petitioners’ and intervenors’ submissions and other stakeholders’ views—would respect institutional boundaries while ensuring that the public-health concerns received objective consideration

The Union must consider those recommendations and make an appropriate, reasoned decision at the earliest; it must also file a compliance affidavit setting out the process, recommendations and decision within two weeks after the Committee’s deadline

The matter was listed for further consideration of that affidavit